These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8071711)

  • 21. Radioimmunotherapy of micrometastases: sidestepping the solid-tumor hurdle.
    Sgouros G
    J Nucl Med; 1995 Oct; 36(10):1910-2. PubMed ID: 7562063
    [No Abstract]   [Full Text] [Related]  

  • 22. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
    Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD
    J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Principles of radioimmunotherapy for hematologists and oncologists.
    Press OW; Rasey J
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):62-73. PubMed ID: 11226002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The determination of the optimal irradiation dose in the tumor tissue-normal body tissues system].
    Klepper LIa
    Med Tekh; 1997; (4):18-21. PubMed ID: 9379858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TCP and NTCP: a basic introduction.
    Baumann M; Petersen C
    Rays; 2005; 30(2):99-104. PubMed ID: 16294901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How far have we come with solid (nonhematologic) tumor radioimmunotherapy?
    Breitz HB
    J Nucl Med; 2000 Dec; 41(12):2011-4. PubMed ID: 11138686
    [No Abstract]   [Full Text] [Related]  

  • 27. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
    Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L
    J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determination of biological vector characteristics and nanoparticle dimensions for radioimmunotherapy with radioactive nanoparticles.
    Nuttens VE; Wéra AC; Bouchat V; Lucas S
    Appl Radiat Isot; 2008 Feb; 66(2):168-72. PubMed ID: 17913502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Value of multiple daily doses in radiotherapy: hyperfractionation].
    Girinsky T; Cosset JM; Malaise EP
    Rev Prat; 1990 Mar; 40(8):735-7. PubMed ID: 2320899
    [No Abstract]   [Full Text] [Related]  

  • 30. Optimization of radiotherapy using biological parameters.
    Kim Y; Tomé W
    Cancer Treat Res; 2008; 139():257-78. PubMed ID: 18236720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
    Juweid M; Sharkey RM; Swayne LC; Griffiths GL; Dunn R; Goldenberg DM
    J Nucl Med; 1998 Jan; 39(1):34-42. PubMed ID: 9443735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mathematical models of cumulative effect and optimization of fractionation regimes.
    Judas L; Lokajícek M; Prokes K
    Strahlenther Onkol; 1988 Feb; 164(2):111-6. PubMed ID: 3344478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overview of dosimetry for Systemic Targeted Radionuclide Therapy (STaRT).
    Wessels BW; Syh JH; Meredith RF
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S39-45. PubMed ID: 16979438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Alpha-radioimmunotherapy: a review of recent developments].
    Supiot S; Thillays F; Rio E; Mahé MA; Barbet FJ; Kraeber-Bodéré F; Chérel M
    Cancer Radiother; 2007 Sep; 11(5):252-9. PubMed ID: 17604673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
    Juweid ME; Hajjar G; Stein R; Sharkey RM; Herskovic T; Swayne LC; Suleiman S; Pereira M; Rubin AD; Goldenberg DM
    J Nucl Med; 2000 Jan; 41(1):93-103. PubMed ID: 10647610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three-dimensional dosimetry for intralesional radionuclide therapy using mathematical modeling and multimodality imaging.
    Flux GD; Webb S; Ott RJ; Chittenden SJ; Thomas R
    J Nucl Med; 1997 Jul; 38(7):1059-66. PubMed ID: 9225791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced renal toxicity of total body irradiation combined with radioimmunotherapy.
    Röttinger EM; Bartkowiak D; Bunjes D; Wennauer R; Dohr D
    Strahlenther Onkol; 2003 Oct; 179(10):702-7. PubMed ID: 14566479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2.
    Juweid ME; Sharkey RM; Behr T; Swayne LC; Dunn R; Siegel J; Goldenberg DM
    J Nucl Med; 1996 Sep; 37(9):1504-10. PubMed ID: 8790202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical and radiobiologic evaluation of radiation dosage in radiotherapy of vaginal cancer].
    Kanaev SV; Turkevich VG
    Vopr Onkol; 1996; 42(6):44-7. PubMed ID: 9123901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis.
    Koppe MJ; Hendriks T; Boerman OC; Oyen WJ; Bleichrodt RP
    J Nucl Med; 2006 Nov; 47(11):1867-74. PubMed ID: 17079821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.